Navigation Links
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Date:6/4/2009

COPENHAGEN, June 4 /PRNewswire/ -- Santaris Pharma today announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma. The study data, which was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Florida last week, demonstrated that EZN-2968 is well tolerated, and that early signs of clinical benefit - prolonged stable disease - were observed in several patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"We have yet to see a dose limiting toxicity and we continue to be encouraged by the early clinical signals in this program," said Jeffrey H. Buchalter, Enzon's Chairman and Chief Executive Officer. "The duration of clinical benefit in certain histologies has exceeded our expectations at this phase of development. We look forward to advancing this promising compound into Phase II trials later this year, once a dose is determined."

"We are encouraged by the progress in the development of this LNA-based HIF-1 alpha inhibitor. The fact that LNA-based RNA inhibitors are beginning to show signs of clinical benefit in cancer patients is very rewarding and is further evidence of the potential of our LNA Drug Platform to generate effective and safe medicines to treat important diseases across a broad range of therapeutic areas," said S0ren Tulstrup, President & CEO of Santaris Pharma A/S.

HIF-1 alpha is a well-validated target in many common solid tumors. EZN-2968 is the first drug candidate to target the HIF-1 transcription factor, which regulates expression of many key genes i
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
7. AlphaVax Announces New CMV Advisory Board
8. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Researchers in India have demonstrated that producing nanoscopic crystals of ... by the gut even if the drug is not soluble ... the medicinal drugs being developed by the pharmaceutical industry dissolve ... a major problem for administering such drugs as it means ...
... ANGELES, Oct. 6 Entertain and interact.  That,s ... . ( www.drfresh.com ), the creator of the ... company behind the successful revival of the ... http://photos.prnewswire.com/prnh/20101006/LA77977LOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20101006/LA77977LOGO ) ...
... Inc. Against the Company And Certain of Its Subsidiaries ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Nano drugs 2A 'Fresh' Approach to Marketing: Dr. Fresh™, Inc. Goes Guerilla With Internet-Based Campaigns 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 3Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 4Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 5Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 6Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 7Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 8Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 9
(Date:7/13/2014)... New research raises the prospect of more effective ... muscle occurring in about half of all cancer patients, ... Dana-Farber Cancer Institute. , Many strategies have been tried ... that patients can,t endure potentially life-saving treatments, but none ... July 13 advanced online edition of Nature , ...
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and under-diagnosed genetic disease in humans just may be ... College of Georgia researchers report. They are pursuing a ... wet form of macular degeneration, the leading cause of blindness ... iron, known to wreak cumulative havoc on the body,s organs, ...
... the tenth anniversary of the completion of the first draft of ... to complete the Wellcome Trust today launches a project to ... This will be one of the largest genome sequencing programmes ever ... in 6,000 people in the UK. The UK10K project is ...
... in German . , Missour/Leipzig. In ... African bird species with a very distinctive courtship behaviour, ... of the same species positively affects brooding females, improving ... birds in the experiment were more fertile and had ...
Cached Biology News:Link between iron overload and macular degeneration under study 2Link between iron overload and macular degeneration under study 3Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3
... CTI Molecular Imaging's proprietary Focus™ detector ... and a large imaging volume that ... image multiple mice or large primateswithout ... dedicated small animal PET (Positron Emission ...
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Biology Products: